The Medical Letter on Drugs and Therapeutics
Vigabatrin (Sabril) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years (REF 1). Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.

MECHANISM OF ACTION — Vigabatrin increases CNS concentrations of gamma-aminobutyric acid (GABA) by inhibiting GABA-transaminase. Increased GABA concentrations may decrease seizure activity.

CLINICAL STUDIES — Complex Partial Seizures ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vigabatrin (Sabril) for Epilepsy
Article code: 1332b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian